Argenx SE (ARGX) has entered into a definitive agreement to acquire Forte Biosciences, Inc. (FBRX), a U.S.-based biotech company, for $77 per share in cash, totaling $2.2 billion. This acquisition is a strategic move to secure FB102, Forte's lead pipeline asset, a first-in-class anti-CD122 monoclonal antibody. Argenx aims to diversify its existing portfolio of autoimmune disease therapies and strengthen its market position through this significant deal. The pre-existing investment relationship between Argenx and Forte as strategic partners facilitated the rapid execution of the M&A.

FB102, the key asset driving the acquisition, is a first-in-class monoclonal antibody targeting CD122 (the interleukin-2/15 receptor beta subunit), selectively inhibiting the activity of pathogenic T cells and NK cells. Phase 1b clinical trial data, released on July 9, 2026, demonstrated promising efficacy in 43 patients with vitiligo. At week 24 of drug administration, the treatment showed a mean improvement of 29.6% in the Facial Vitiligo Area Severity Index (FVASI) compared to baseline, significantly outperforming the placebo group's 7.9%. Furthermore, the severe patient subgroup with extensive lesions achieved an improvement of 43.2%, demonstrating its potential as a next-generation therapy.

The global vitiligo market is currently valued at approximately $1.84 billion as of 2025 and is expected to continue growing, making it a promising market. Incyte's topical JAK inhibitor, Opzelura, which received FDA approval in July 2022, is currently the only targeted therapy on the market. However, its topical application limits its use in treating severe patients who require systemic administration. FB102, with its systemic action, can target not only vitiligo but also celiac disease (market size of approximately $600 million to $970 million in 2025) and alopecia areata, offering broader applicability. Argenx is therefore implementing a strategy to simultaneously address multiple autoimmune diseases with high unmet needs.

Argenx is actively diversifying its pipeline through its 'Vision 2030' initiative, building on the success of its lead drug, Vyvgart. The CD122-targeting mechanism has a unique mode of action, preserving the function of regulatory T cells (Treg) while blocking inflammatory cytokine pathways. Through this acquisition, Argenx aims to integrate Forte's systemic immune modulation platform with its own expertise in antibody engineering, maximizing synergy. This acquisition is expected to be more than just the introduction of a single drug; it is expected to establish a versatile new drug platform applicable to various immune diseases.